Mohammed Bari, MD
Psychiatry · National City, CANPI 1679588370
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 915 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,695, 4.1 times the $1,379 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 915 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$3K
- AbbVie$2K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- plus $8K from 24 others
Across 942 payments — averaging $6190.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$959K
- Sumitomo Pharma America, Inc.$823K
- Teva Pharmaceuticals USA, Inc.$704K
- Sunovion Pharmaceuticals Inc.$550K
- Hoffmann-la Roche Limited$389K
- Biohaven Pharmaceuticals, Inc.$360K
- plus $2M from 26 others
What the payments were for
- Food & beverage$21,00499%
- Education$1941%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 115 | $2,860 |
| Otsuka America Pharmaceutical, Inc. | 113 | $2,583 |
| AbbVie(2 entities) | 118 | $2,370 |
| Neurocrine Biosciences, Inc. | 94 | $1,975 |
| Teva Pharmaceuticals USA, Inc. | 73 | $1,812 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 77 | $1,668 |
| Johnson & Johnson | 57 | $1,445 |
| Vanda Pharmaceuticals Inc. | 53 | $1,309 |
| Axsome Therapeutics, Inc. | 19 | $1,104 |
| Lundbeck LLC | 47 | $947 |
| E.r. Squibb & Sons, L.L.C. | 43 | $913 |
| Sunovion Pharmaceuticals Inc. | 42 | $715 |
| Indivior Inc. | 25 | $518 |
| Acadia Pharmaceuticals Inc | 6 | $222 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $128 |
| CSL Behring | 1 | $125 |
| Livanova USA, Inc. | 4 | $83 |
| Sun Pharmaceutical Industries Inc. | 2 | $69 |
| Idorsia Pharmaceuticals US Inc | 3 | $61 |
| Noven Therapeutics, LLC | 3 | $49 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $45 |
| Novo Nordisk | 2 | $34 |
| Luye Pharma (USA) Ltd. | 1 | $34 |
| Eisai Inc. | 2 | $30 |
| Merck | 1 | $23 |
| Corium, LLC | 1 | $19 |
| Noven Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,842
- ARISTADA$1,479
- Auvelity$799
- REXULTI$582
- COBENFY$496
- Fanapt$371
- ARISTADA INITIO$370
- ABILIFY MAINTENA$352
- INVEGA SUSTENNA$270
- INGREZZA$264
- VRAYLAR$248
- UZEDY$244
- CAPLYTA$234
- ABILIFY ASIMTUFII$232
- AUSTEDO$219
- Hizentra$125
- NUPLAZID$114
- Rinvoq$112
How this compares
$21,198 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 403 | $1,363,374 |
| IngrezzaValbenazine Tosylate | 84 | $658,542 |
| Abilify MaintenaAripiprazole | 204 | $571,212 |
| AustedoDeutetrabenazine | 50 | $323,132 |
| VraylarCariprazine Hcl | 86 | $167,022 |
| AristadaAripiprazole Lauroxil | 54 | $164,318 |
| UzedyRisperidone | 41 | $123,862 |
| RexultiBrexpiprazole | 48 | $71,074 |
| LybalviOlanzapine/Samidorphan Malate | 31 | $49,004 |
| Clozapine | 428 | $42,601 |
| Clozapine OdtClozapine | 39 | $36,208 |
| CaplytaLumateperone Tosylate | 21 | $35,470 |
| Lurasidone Hcl | 123 | $33,495 |
| Paliperidone ErPaliperidone | 50 | $20,251 |
| Quetiapine Fumarate | 687 | $17,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,445 | $1,363,374403 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,975 | $658,54284 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $2,583 | $642,286252 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,812 | $446,99391 claims |
| Alkermes, Inc.Aristada, Lybalvi | $2,860 | $213,32285 claims |
| AbbVieVraylar, Saphris | $2,370 | $181,93498 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,668 | $35,47021 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $128 | $9,93024 claims |
| MerckBelsomra | $23 | $5,94014 claims |
| Almatica Pharma LLCSertraline Hcl | $15 | $1,844167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in National City
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.